iCo Therapeutics Inc.

Recent News

  • iCo Therapeutics Inc. Announces the Issuance of 41,200,000 Units Pursuant to its Non-Brokered Private Placement

    Vancouver, British Columbia--(Newsfile Corp. - August 19, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") is pleased to announce that it has issued 41,200,000 units ("Units") pursuant to a non-brokered private placement (the "Private Placement"). The Units were sold at a price of $0.05 ...

    2019-08-19 8:00 AM ET
  • iCo Therapeutics Provides Corporate Update

    Vancouver, British Columbia--(Newsfile Corp. - August 6, 2019) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today provided an update with respect to the Company's clinical and regulatory path for its Oral Amphotericin B (Oral Amp B) candidate. During Q2 2019, iCo submitted a plan and further ...

    2019-08-06 10:45 PM ET
  • iCo Therapeutics Announces AGM Voting Results

    Vancouver, British Columbia--(Newsfile Corp. - June 28, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today announced the results of voting at its 2019 Annual General Meeting of Shareholders held on June 27, 2019.A total of 20,801,184 common shares were voted in connection with the ...

    2019-06-28 8:00 AM ET
  • iCo Therapeutics Announces First Quarter 2019 Financial Results

    Vancouver, British Columbia--(Newsfile Corp. - May 30, 2019) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the Quarter ended March 31, 2019. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").Stated Andrew Rae, President ...

    2019-05-30 4:39 PM ET
  • iCo Therapeutics Announces 2018 Year End Financial Results

    Vancouver, British Columbia--(Newsfile Corp. - April 30, 2019) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the year ended December 31, 2018. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").Stated Andrew Rae, President ...

    2019-04-30 6:37 PM ET
  • iCo Therapeutics Inc. Announces the Issuance of 3,600,000 Units Pursuant to its Non-Brokered Private Placement

    Vancouver, British Columbia--(Newsfile Corp. - March 5, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") is pleased to announce that it has issued a further 3,600,000 units ("Units") pursuant to its previously announced non-brokered private placement (the "Private Placement"). The Units were sold at ...

    2019-03-05 8:25 AM ET
  • iCo Therapeutics Inc. Announces the Issuance of 14,400,000 Units Pursuant to its C$1,250,000 Non-Brokered Private Placement

    Vancouver, British Columbia--(Newsfile Corp. - February 25, 2019) -  iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") is pleased to announce that it has issued a total of 14,400,000 units (the "Units") pursuant to its previously announced non-brokered private placement (the "Private Placement"). The Units were sold ...

    2019-02-25 9:00 AM ET
  • iCo Therapeutics Inc. Announces Upsizing of Non-Brokered Private Placement to $1,250,000 CDN

    Vancouver, British Columbia--(Newsfile Corp. - February 19, 2019) -  iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") announces an upsizing of a previously announced Non-brokered private placement to $1,250,000 CDN.Each Unit issued pursuant to the Private Placement consists of one common share in the capital of the ...

    2019-02-19 7:00 AM ET